XLS Medical Appetite Reducer - Appetite Suppressant and Hunger Control for a more Efficient Weight Loss - 60 Capsules, 10 Days Treatment

Product Information

The primary endpoint of this study was the comparison of the mean body weight (kg) change between IQP-AE-103 high dose and placebo after 12 weeks of intervention from baseline, in overweight and moderately obese subjects. The evaluation of the efficacy of IQP-AE-103 was based on the null hypothesis that there are no statistical differences between IQP-AE-103 and placebo in mean reduction of body weight after 12 weeks of treatment. The nonparametric Mann–Whitney U test for independent samples was applied. The testing was carried out by the determination of the rank sum of individual body weight changes. In our study, BMI, body fat mass, and waist and hip circumference were also found to be decreased significantly in both IQP-AE-103 dose groups. Lowering waist circumference, a marker of abdominal fat content, indicates that the treatment with IQP-AE-103 could potentially lower the risk of diabetes, coronary heart disease, and nonalcoholic fatty liver disease [ 42– 44]. Additionally, the changes in fat-free mass were not significantly different between the treatment groups, indicating that the weight loss effect was primarily due to body fat reduction. In the next step, the weight loss and weight maintenance efficacy of IQP-AE-103 should be evaluated in longer clinical trials. Also, it would be worthwhile to further investigate any positive effect on cardiovascular risk factors associated with obesity, particularly in subjects with elevated blood lipids. For further elucidation of mode of action, an assessment of fecal fat excretion, or postprandial blood lipid changes and potentially gut microbiome study could be considered. 5. Conclusion and Implication

Do not take Hunger Buddy during pregnancy or whilst breastfeeding, or if your BMI (Body Mass Index) is below 18.5. It is recommended that you calculate your BMI before and during use. InQpharm NA, the company that brought plant-based, weight-loss system bmiSMART to the US, has announced the publication of a double-blind, placebo-controlled 14-week study in Advancement in Medicinal Plant Research, revealing significant benefits of appetite reduction on weight loss. Plants have always been a good source of new potential and natural therapies for illnesses, including body weight management products. Litramine®, a natural fibre complex derived from Opuntia ficus-indica, enriched with soluble fibres from Acacia sp., has been shown in a number of clinical trials to safely and effectively reduce and maintain weight loss [ 17– 20]. Litramine® has been demonstrated to reduce dietary fat absorption and increase fecal fat excretion, resulting in lower calorie absorption from diet, which leads to weight loss [ 20, 21]. B. Grube, et al., “IQP-VV-102, A Novel Proprietary Composition for Weight Reduction: A Double-Blind Randomized Clinical Trial for Evaluation of Efficacy and Safety,” Evidence-Based Complementary and Alternative Medicine: http://dx.doi.org/10.1155/2015/413075 (2015). The REDUSURE trademark was assigned an Application Number # 1756268 by the Canadian Intellectual Property Office (CIPO).

Warnings

The animal and in vitro data used to support the findings of this study are currently under embargo, whereas the research findings are commercialized. Data requests will be considered by the corresponding author 12 months after publication of this article. Conflicts of Interest

All other efficacy as well as the safety and concurrent variables were exploratively examined and were descriptively assessed. For the metric data (continuous data), the statistical characteristics were given (number, mean, standard deviation, median, extremes, quartiles, and 95% confidence interval of mean). For ordinal data (discrete data), frequency distribution was performed. All nominal data (categorical data) were summarized using frequency tables. All variables were evaluated primarily by exact nonparametric procedures: (i) Kruskal–Wallis test for more than two independent groups (comparison of groups or subgroups) (ii) Mann–Whitney U test for independent groups (comparison of groups or subgroups) (iii) Wilcoxon test for dependent groups (comparison of pre-post within groups or subgroups) (iv) Fisher’s exact test for comparison of percentage. Our study has several limitations. One limitation is that it was performed over a short period of only 12 weeks, with no follow-up conducted after the study was finished and no weight maintenance phase after the initial weight loss. As such, the study provides no information about the effects of IQP-AE-103 on long-term weight maintenance and on other obesity-related conditions such as diabetes or cardiovascular disease. In addition, the study included subjects of a wide age range. Although the distribution of different age groups was not substantially different between groups in the current study, it may be helpful to include age as a stratification factor in future study. Changes in gut microbiota composition occur with age [ 52], and it has been shown that altered gut microbiota may be associated with obesity [ 53], since IQP-AE-103 contains fibres and polysaccharides from okra pod and inulin, it is likely that the composition of the intestinal gut microbiota may be positively influenced by the consumption of IQP-AE-103. Hence, analysis of gut microbiota changes in overweight and obese subjects of different age groups may provide additional knowledge regarding the effect of IQP-AE-103. Moreover, appetite sensations in the study were assessed using VAS and rating scales, which were not validated for the specific use to measure changes in a similar study design. Last but not least, self-reporting of dietary intake by study subjects, applied for reasons of practicality, may be a limitation. It is known that factors such as gender and weight status affect subjects’ behavior in reporting energy intake; for example, females tended to underreport compared with males, and increasing weight status was associated with an increase in underreporting of energy intake [ 54]. As such, results obtained in the current study, primarily evaluating weight loss, on IQP-AE-103’s effect on appetite sensations remain exploratory. To evaluate a potential effect of IQP-AE-103 on food/energy intake, quantification of actual calorie intake by recording food consumption at an “ad libitum” lunch may be considered in future studies. B. Grube, et al., “A Natural Fiber Complex Reduces Body Weight in the Overweight and Obese: A Double-Blind, Randomized, Placebo-Controlled Study,” Obesity 21, 58–64 (2013). During the intervention period, no significant changes in fasting blood glucose and HbA1c levels were observed between the study groups. 67% of subjects in the IQP-AE-103 high-dose group had a reduction in triglyceride levels compared with 37% in the placebo group ( ). Changes in total/low-density lipoprotein (LDL)/high-density lipoprotein (HDL) cholesterol were not significant at the end of the study, but a post hoc subgroup analysis performed with subjects with baseline total cholesterol level above 6.2 mmol/L revealed pre-post reductions in total cholesterol of 1.22 ± 1.10 mmol/L ( ), 0.58 ± 0.90 mmol/L ( ), 0.13 ± 0.31 mmol/L ( ), and reductions in LDL cholesterol of 1.18 ± 1.06 mmol/L ( ), 0.49 ± 0.74 mmol/L ( ), and 0.23 ± 0.29 mmol/L ( ), in high-dose, low-dose IQP-AE-103, and placebo groups, respectively. At the end of the study, 97.1% of the subjects in the high-dose IQP-AE-103 group and 85.3% in the low-dose group rated the benefits of the treatment as “good” or “very good” compared with 10% in the placebo group. However, investigator rated the benefit as “good” or “very good” for 94.1% and 85.3% of the subjects in high- and low-dose IQP-AE-103 groups, respectively, compared with 6.7% for placebo subjects.Obesity is the fastest growing chronic disease — one that affects people of all ages. Its concomitant health risks are well documented, as is its role in the progression of other diseases, including cardiovascular disease, type 2 diabetes, respiratory problems and osteoarthritis. 1 Another finding of this study is that besides weight loss, IQP-AE-103 showed beneficial effects on lipid metabolism. A significantly higher proportion of subjects in the high-dose IQP-AE-103 group experienced a reduction in triglyceride levels at the end of the study compared with placebo. In subjects with higher baseline total cholesterol levels (>6.2 mmol/L), high dose of IQP-AE-103 was shown to significantly reduce total cholesterol and LDL-cholesterol (pre-post change). Therefore, current outcome suggests that long-term treatment with IQP-AE-103 could be beneficial for subjects with elevated blood lipid levels in reducing the risk of cardiovascular disease.